Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Ernexa Therapeutics Inc. (ERNA)
USD6.73
+0.67 (+11.06%)
US NASDAQ Healthcare Biotechnology
Address
10355 Science Center Drive 92121
Cambridge, MA, US
Cambridge, MA, US
CEO
Sanjeev Luther
Website
ernexatx.com
IPO
1991-08-29
CIK 748592 ISIN US1140824079
Description
Ernexa Therapeutics Inc. is a biotechnology firm currently in its preclinical development phase, specializing in the creation of therapeutic interventions using induced mesenchymal stem cells (iMSCs). The company's primary focus lies in addressing solid tumor cancers and a range of autoimmune diseases. Its flagship candidate, ERNA-101, is an allogeneic iMSC designed to release pro-inflammatory cytokines, namely IL-7 and IL-15, intended for the treatment of ovarian cancer. Additionally, Ernexa is developing ERNA-102, an iMSC product engineered to secrete the anti-inflammatory cytokine IL-10, aimed at managing rheumatoid arthritis. The company has a licensing arrangement in place with Factor Bioscience Limited. Established in 2018, this Cambridge, Massachusetts-based entity operated as Eterna Therapeutics Inc. until its rebranding to Ernexa Therapeutics in March 2025.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD6.73
+0.67 (+11.06%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
2M
Beta
2.51
Float Shares
99.8K
Free Float %
31.8%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +66.57% | +55.17% | +144.11% | +48.64% | -69.40% | -59.97% | -85.40% | -98.89% | -99.99% | -99.99% | -100.00% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
6.73
DCF (Unlevered)
1.88
-72.1%
DCF (Levered)
5.53
-17.9%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
0% Bullish
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-35.80
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
0 / 10
No MOAT
Composite Rating
B-
Overall Score
3 / 5
Medium
DCF Score
4 / 5
High
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
5 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-100.0%
-
EPS growth Biotechnology: +29.7%-42.7% Q1'26: -85.3% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%-925.4% Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%-77.8% ★ Q1'26: -62.9% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.05× Q1'26: -0.02× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 EPS Ana. |
Dec 2028 1 EPS Ana. |
Dec 2029 1 EPS Ana. |
Dec 2030 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
24.52M
est: 24.52M (+0.0%)
|
22.31M
est: 24.52M (-9.0%)
|
21.27M
est: 22.33M (-4.7%)
|
23.34M
est: 21.48M (+8.6%)
|
19.81M
est: 24.35M (-18.6%)
|
—
est: 25.63M (-100.0%)
|
—
est: 32.81M (-100.0%)
|
75.35M
75.35M – 75.35M
+129.6% YoY
|
—
— – —
-100.0% YoY
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBITDA |
-3.63M
est: 4.90M (-173.9%)
|
609.0K
est: 4.90M (-87.6%)
|
915.0K
est: 4.47M (-79.5%)
|
3.23M
est: 4.30M (-24.9%)
|
1.40M
est: 4.87M (-71.3%)
|
-26.39M
est: 5.13M (-614.8%)
|
-9.06M
est: 6.56M (-238.0%)
|
15.07M
15.07M – 15.07M
+129.6% YoY
|
—
— – —
-100.0% YoY
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-6.73M
est: 4.90M (-237.2%)
|
-2.31M
est: 4.90M (-147.1%)
|
-513.0K
est: 4.47M (-111.5%)
|
66.0K
est: 4.30M (-98.5%)
|
-1.77M
est: 4.87M (-136.4%)
|
-26.49M
est: 5.13M (-616.7%)
|
-9.32M
est: 6.56M (-242.0%)
|
15.07M
15.07M – 15.07M
+129.6% YoY
|
—
— – —
-100.0% YoY
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-7.23M
est: -30.48M (+76.3%)
|
-2.92M
est: -30.48M (+90.4%)
|
-1.08M
est: -227.05M (+99.5%)
|
-259.0K
est: -49.95M (+99.5%)
|
-2.05M
est: 7.57M (-127.0%)
|
11.91M
est: 21.19M (-43.8%)
|
-14.10M
est: -1.02B (+98.6%)
|
-2.37M
-2.37M – -2.37M
+99.8% YoY
|
-297.7K
-297.7K – -297.7K
+87.4% YoY
|
-232.1K
-232.1K – -232.1K
+22.0% YoY
|
-262.4K
-262.4K – -262.4K
-13.0% YoY
|
-295.2K
-295.2K – -295.2K
-12.5% YoY
|
| SGA |
18.06M
est: 1.18B (-98.5%)
|
16.46M
est: 1.18B (-98.6%)
|
15.45M
est: 1.07B (-98.6%)
|
14.41M
est: 1.03B (-98.6%)
|
13.15M
est: 1.17B (-98.9%)
|
3.30M
est: 1.23B (-99.7%)
|
5.16M
est: 1.58B (-99.7%)
|
3.62B
3.62B – 3.62B
+129.6% YoY
|
—
— – —
-100.0% YoY
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-3,931.50
est: -120.83 (-3,153.9%)
|
-1,536.00
est: -120.83 (-1,171.2%)
|
-441.00
est: -900.00 (+51.0%)
|
-96.25
est: -198.00 (+51.4%)
|
-712.00
est: 30.00 (-2,473.3%)
|
-87.75
est: 84.00 (-204.5%)
|
-56.00
est: -4,050.00 (+98.6%)
|
-9.38
-9.38 – -9.38
+99.8% YoY
|
-1.18
-1.18 – -1.18
+87.4% YoY
|
-0.92
-0.92 – -0.92
+22.0% YoY
|
-1.04
-1.04 – -1.04
-13.0% YoY
|
-1.17
-1.17 – -1.17
-12.5% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-11 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-08 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-07 | C | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-06 | C | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-05 | C | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-04 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-01 | C | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-30 | C | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-29 | C | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-28 | C | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-27 | C | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-24 | C | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-23 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-22 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-21 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-20 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-17 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-16 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-8.47M
OE per share TTM
-26.62
Owner's Yield
-89.08%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
228.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
5
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Huff | 1.05M | 19.99% | — | 1.05M | — | 1.05M | IN | Texas | 2023-07-21 | ↗ |
| 2 | Investments LLC | 1.05M | 19.99% | — | 1.05M | — | 1.05M | OO | Texas | 2023-07-21 | ↗ |
| 3 | LP | 1.05M | 19.99% | — | 1.05M | — | 1.05M | PN | Texas | 2023-07-21 | ↗ |
| 4 | IAF, LLC | 577.0K | 9.99% | 577.0K | — | 577.0K | — | OO | South Carolina | 2023-12-20 | ↗ |
| 5 | Purchase Capital LLC | 280.4K | 5.00% | 121.8K | — | 280.4K | — | OO | Delaware | 2023-08-28 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 1 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard Extended Market ETF VXF | 0.00% | 58.7K | 0.05% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
2
Sells
0
Shares acquired
25.01M
Shares disposed
—
Cash buys
2.00
Cash sales
—
Net activity
+25,009,560
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-02-10 | Cherington Charles | 10% Owner | P-Purchase | A | Common Stock | 4,000,000 | 0.50 | 2.00M | 6,779,440 | D | ↗ |
| 2025-06-21 | Gurrola Sandra M | Officer | M-Exempt | A | Common Stock | 30 | 0.00 | — | 110 | D | ↗ |
| 2025-06-09 | Cherington Charles | 10% Owner | P-Purchase | A | Common Stock | 21,241,163 | 0.10 | 2.22M | 41,659,743 | D | ↗ |
| 2025-04-02 | Cherington Charles | 10% Owner | P-Purchase | A | Common Stock | 3,768,397 | 0.10 | 394.2K | 20,401,602 | D | ↗ |
| 2025-02-20 | Menge Steven Reid | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-02-20 | Kim Tony | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-02-07 | Wexler William A. | Director | A-Award | A | Stock Option (right to buy) | 124,533 | 0.34 | 42.3K | 124,533 | D | ↗ |
| 2025-02-07 | Luther Sanjeev | Director / Officer | A-Award | A | Stock Option (right to buy) | 1,123,350 | 0.34 | 381.9K | 1,123,350 | D | ↗ |
| 2025-02-07 | Gurrola Sandra M | Officer | A-Award | A | Stock Option (Right to buy) | 150,000 | 0.34 | 51.0K | 150,000 | D | ↗ |
| 2025-02-07 | Cicala Peter | Director | A-Award | A | Stock Option (Right to buy) | 51,485 | 0.34 | 17.5K | 51,485 | D | ↗ |
| 2025-02-07 | Bristol James Arthur | Director | A-Award | A | Stock Option (Right to buy) | 72,074 | 0.34 | 24.5K | 72,074 | D | ↗ |
| 2025-01-13 | Ratner Elena | Director | A-Award | A | Stock Option (Right to buy) | 140,078 | 0.30 | 42.0K | 140,078 | D | ↗ |
| 2025-01-07 | Ratner Elena | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-10-29 | Cherington Charles | 10% Owner | P-Purchase | A | Common Stock | 4,768,783 | 1.00 | 4.77M | 5,587,004 | D | ↗ |
| 2024-09-24 | Cherington Charles | 10% Owner | P-Purchase | A | Common Stock | 4,768,783 | 0.00 | — | 5,587,004 | D | ↗ |
| 2024-09-23 | Cherington Charles | 10% Owner | P-Purchase | A | Warrants (right to buy) | 83,916 | 1.43 | 120.0K | 2,475,524 | D | ↗ |
| 2024-06-21 | Gurrola Sandra M | Officer | F-InKind | D | Common Stock | 180 | 1.94 | 349.20 | 1,185 | — | ↗ |
| 2024-04-26 | Gurrola Sandra M | Officer | A-Award | A | Stock Option (Right to buy) | 80,000 | 1.74 | 139.2K | 80,000 | — | ↗ |
| 2024-04-26 | Cicala Peter | Director | A-Award | A | Stock Option (Right to buy) | 88,946 | 1.74 | 154.8K | 88,946 | — | ↗ |
| 2024-04-26 | Bristol James Arthur | Director | A-Award | A | Stock Option (Right to buy) | 124,525 | 1.74 | 216.7K | 124,525 | — | ↗ |
| 2024-02-12 | Cicala Peter | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-01-01 | Luther Sanjeev | Director / Officer | A-Award | A | Stock Option (right to buy) | 1,685,218 | 1.80 | 3.03M | 1,685,218 | — | ↗ |
| 2024-01-01 | Clarke Dorothy J | Director / Officer | A-Award | A | Stock Option (right to buy) | 168,521 | 1.80 | 303.3K | 168,521 | — | ↗ |
| 2023-12-15 | Freebird Partners LP | 10% Owner | P-Purchase | A | Common Stock Purchase Warrant | 1,041,992 | 1.43 | 1.49M | 1,991,394 | — | ↗ |
| 2023-12-14 | Freebird Partners LP | 10% Owner | D-Return | A | Common Stock Purchase Warrant | 524,474 | 2.61 | 1.37M | 424,928 | — | ↗ |
| 2023-12-14 | Cherington Charles | 10% Owner | P-Purchase | A | Warrants (right to buy) | 2,307,692 | 1.43 | 3.30M | 2,307,692 | — | ↗ |
| 2023-10-30 | Bristol James Arthur | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-08-28 | Clarke Dorothy J | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-08-08 | WAGNER RICHARD W | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-08-08 | BINDER BRANT | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-07-14 | Freebird Partners LP | 10% Owner | P-Purchase | A | Convertible Note Shares | 262,237 | 2.86 | 750.0K | 262,237 | — | ↗ |
| 2023-07-13 | WAGNER RICHARD W | Director | P-Purchase | A | Warrants (right to buy) | 83,916 | 2.61 | 219.0K | 83,916 | — | ↗ |
| 2023-07-13 | Cherington Charles | 10% Owner | P-Purchase | A | Warrants (right to buy) | 2,307,692 | 2.61 | 6.02M | 2,307,692 | — | ↗ |
| 2023-07-13 | BINDER BRANT | Director | P-Purchase | A | 6.0% Senior Convertible Promissory Notes due 2028 | 0 | 2.86 | — | 0 | — | ↗ |
| 2023-07-06 | WAGNER RICHARD W | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-07-06 | BINDER BRANT | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-06-21 | Gurrola Sandra M | Officer | F-InKind | D | Common Stock | 179 | 2.48 | 443.92 | 928 | — | ↗ |
| 2023-06-02 | Freebird Partners LP | 10% Owner | — | D | Common Stock Purchase Warrant | 424,928 | 3.28 | 1.39M | 0 | — | ↗ |
| 2023-04-03 | Freebird Partners LP | 10% Owner | — | D | Common Stock, par value $0.005 per share | 0 | 0.00 | — | 272,582 | — | ↗ |
| 2023-01-12 | Angel Matthew | Director | A-Award | A | Stock Option (right to buy) | 132,003 | 0.00 | — | 132,003 | — | ↗ |
| 2022-12-02 | Singer Nicholas Jason | Director | P-Purchase | A | Common Stock | 70,822 | 3.28 | 232.3K | 121,822 | — | ↗ |
| 2022-12-02 | HALPERN JOHN D | Director | P-Purchase | A | Warrants (Right to Purchase) | 671,840 | 0.13 | 84.0K | 671,840 | — | ↗ |
| 2022-12-02 | DENNY GEORGE P III | 10% Owner | — | I | Series A Preferred Stock | 2,971 | 0.00 | — | 0 | — | ↗ |
| 2022-12-02 | Cherington Charles | Director | P-Purchase | A | Warrants (right to buy) | 523,512 | 0.13 | 65.4K | 523,512 | — | ↗ |
| 2022-09-20 | Sidhu Roger | Officer | M-Exempt | D | Restricted Stock Units | 20,163 | 0.00 | — | 60,487 | — | ↗ |
| 2022-08-01 | Wexler William A. | Director | A-Award | A | Stock Option (right to buy) | 165,800 | 0.00 | — | 165,800 | — | ↗ |
| 2022-08-01 | Singer Nicholas Jason | Director | A-Award | A | Stock Option (right to buy) | 165,800 | 0.00 | — | 165,800 | — | ↗ |
| 2022-08-01 | Fiore Gregory | Director | A-Award | A | Stock Option (right to buy) | 95,100 | 0.00 | — | 95,100 | — | ↗ |
| 2022-08-01 | Cherington Charles | Director | A-Award | A | Stock Option (right to buy) | 215,100 | 0.00 | — | 215,100 | — | ↗ |
| 2022-08-01 | Angel Matthew | Director | A-Award | A | Stock Option (right to buy) | 2,487,003 | 0.00 | — | 2,487,003 | — | ↗ |
| 2022-06-28 | DAmour Kevin | Director / Officer | M-Exempt | A | Common Stock | 17,573 | 0.00 | — | 17,573 | — | ↗ |
| 2022-06-21 | Gurrola Sandra M | Officer | M-Exempt | D | Restricted Stock Units | 8,750 | 0.00 | — | 26,250 | — | ↗ |
| 2022-06-05 | Wexler William A. | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-06-05 | Singer Nicholas Jason | — | — | I | Common Stock | 0 | 0.00 | — | 1,020,000 | — | ↗ |
| 2022-06-05 | Fiore Gregory | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-06-03 | Jackson Andrew C. | Officer | A-Award | A | Stock Option (right to buy) | 664,800 | 0.61 | 404.6K | 664,800 | — | ↗ |
| 2022-05-31 | Jackson Andrew C. | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-05-26 | Angel Matthew | — | — | I | Common Stock | 0 | 0.00 | — | 2,580,663 | — | ↗ |
| 2022-03-11 | Sidhu Roger | — | A-Award | A | Stock Option (Right to buy) | 142,100 | 1.93 | 274.3K | 142,100 | — | ↗ |
| 2022-03-11 | Sial Jay | Director / Officer | A-Award | A | Stock Option (Right to buy) | 117,200 | 0.00 | — | 117,200 | — | ↗ |
| 2022-03-11 | Gurrola Sandra M | Director | A-Award | A | Stock Option (Right to buy) | 114,500 | 0.00 | — | 114,500 | — | ↗ |
| 2022-03-11 | Federoff Howard J. | Director | A-Award | A | Stock Option (Right to buy) | 413,700 | 0.00 | — | 413,700 | — | ↗ |
| 2022-03-11 | DAmour Kevin | Director / Officer | A-Award | A | Stock Option (Right to buy) | 138,400 | 0.00 | — | 138,400 | — | ↗ |
| 2022-01-14 | Redman Heather B | — | A-Award | A | Stock Option (right to buy) | 67,000 | 3.22 | 215.7K | 67,000 | — | ↗ |
| 2022-01-14 | ENRIGHT ERIN S. | — | A-Award | A | Stock Option (right to buy) | 67,000 | 3.22 | 215.7K | 67,000 | — | ↗ |
| 2021-12-08 | Mohr Erich | — | A-Award | A | Stock Option | 67,000 | 5.94 | 398.0K | 67,000 | — | ↗ |
| 2021-12-08 | LANGER DENNIS | — | A-Award | A | Stock Option | 67,000 | 5.94 | 398.0K | 67,000 | — | ↗ |
| 2021-12-08 | Greenwood Luba | — | A-Award | A | Stock Option | 67,000 | 5.94 | 398.0K | 67,000 | — | ↗ |
| 2021-12-08 | Cherington Charles | — | A-Award | A | Stock Option | 67,000 | 5.94 | 398.0K | 67,000 | — | ↗ |
| 2021-09-20 | Sidhu Roger | — | A-Award | A | Stock Option | 161,300 | 9.96 | 1.61M | 161,300 | — | ↗ |
| 2021-07-15 | Sial Jay | — | A-Award | A | Restricted Stock Unit | 35,700 | 0.00 | — | 35,700 | — | ↗ |
| 2021-07-14 | DENNY GEORGE P III | 10% Owner | P-Purchase | A | Common Stock | 1 | 11.99 | 11.99 | 3 | — | ↗ |
| 2021-07-09 | DENNY GEORGE P III | 10% Owner | P-Purchase | A | Common Stock | 1 | 14.11 | 14.11 | 2 | — | ↗ |
| 2021-07-08 | DENNY GEORGE P III | 10% Owner | P-Purchase | A | Common Stock | 1 | 14.35 | 14.35 | 1 | — | ↗ |
| 2021-07-06 | DENNY GEORGE P III | 10% Owner | S-Sale | D | Common Stock | 75,000 | 16.06 | 1.20M | 4,775,117 | — | ↗ |
| 2021-06-28 | DAmour Kevin | — | A-Award | A | Stock Option | 140,580 | 21.35 | 3.00M | 140,580 | — | ↗ |
| 2021-06-21 | Gurrola Sandra M | — | — | D | Common Stock | 0 | 0.00 | — | 8,203 | — | ↗ |
| 2021-06-17 | Cherington Charles | — | S-Sale | D | Common Stock | 198,000 | 15.74 | 3.12M | 5,896,101 | — | ↗ |
| 2021-06-16 | Cherington Charles | — | S-Sale | D | Common Stock | 200,000 | 15.73 | 3.15M | 6,094,101 | — | ↗ |
| 2021-06-01 | Cherington Charles | — | J-Other | A | Common Stock | 92 | 0.00 | — | 5,894,193 | — | ↗ |
| 2021-05-06 | Mohr Erich | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-05-01 | LANGER DENNIS | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-04-16 | Federoff Howard J. | — | A-Award | A | Stock Option | 2,627,915 | 7.94 | 20.87M | 2,627,915 | — | ↗ |
| 2021-03-25 | Singer Nicholas Jason | — | — | I | Common Stock | 0 | 0.00 | — | 1,891,531 | — | ↗ |
| 2021-03-25 | Monovoukas Yiannis | — | — | I | Common Stock | 0 | 0.00 | — | 560,453 | — | ↗ |
| 2021-03-25 | Mason Lynn Sadowski | — | — | D | Common Stock | 0 | 0.00 | — | 94,333 | — | ↗ |
| 2021-03-25 | HALPERN JOHN D | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 4,094 | — | ↗ |
| 2021-03-25 | Guido Ronald | — | — | D | Common Stock | 0 | 0.00 | — | 102,112 | — | ↗ |
| 2021-03-25 | Greenwood Luba | — | — | D | Common Stock | 0 | 0.00 | — | 50,032 | — | ↗ |
| 2021-03-25 | DENNY GEORGE P III | — | — | I | Common Stock | 0 | 0.00 | — | 34,585 | — | ↗ |
| 2021-03-25 | Cherington Charles | — | — | D | Series A Preferred Stock | 19,196 | 0.00 | — | 0 | — | ↗ |
| 2021-03-24 | Wolff Allen | Director / Officer | F-InKind | D | Common Stock | 9,944 | 2.67 | 26.6K | 128,520 | — | ↗ |
| 2021-03-24 | Gurrola Sandra M | Officer | F-InKind | D | Common Stock | 6,094 | 2.67 | 16.3K | 21,617 | — | ↗ |
| 2021-03-19 | Wolff Allen | Director / Officer | F-InKind | D | Common Stock | 207 | 3.53 | 730.71 | 138,464 | — | ↗ |
| 2021-03-19 | Gurrola Sandra M | Officer | F-InKind | D | Common Stock | 116 | 3.53 | 409.48 | 27,711 | — | ↗ |
| 2021-02-19 | Wolff Allen | Director / Officer | F-InKind | D | Common Stock | 207 | 4.81 | 995.67 | 138,671 | — | ↗ |
| 2021-02-19 | Gurrola Sandra M | Officer | F-InKind | D | Common Stock | 115 | 4.81 | 553.15 | 27,827 | — | ↗ |
| 2021-01-19 | Wolff Allen | Director / Officer | F-InKind | D | Common Stock | 2,987 | 2.55 | 7.6K | 138,878 | — | ↗ |
| 2021-01-19 | Gurrola Sandra M | Officer | F-InKind | D | Common Stock | 1,400 | 2.55 | 3.6K | 27,942 | — | ↗ |
| 2020-12-19 | Wolff Allen | Director / Officer | F-InKind | D | Common Stock | 170 | 2.17 | 368.90 | 141,865 | — | ↗ |
| 2020-12-19 | Gurrola Sandra M | Officer | F-InKind | D | Common Stock | 100 | 2.17 | 217.00 | 29,342 | — | ↗ |
| 2020-11-20 | Wolff Allen | Director / Officer | F-InKind | D | Common Stock | 170 | 1.88 | 319.60 | 142,035 | — | ↗ |
| 2020-11-20 | Gurrola Sandra M | Officer | F-InKind | D | Common Stock | 98 | 1.88 | 184.24 | 29,442 | — | ↗ |
| 2020-10-21 | Wolff Allen | Director / Officer | F-InKind | D | Common Stock | 2,453 | 2.05 | 5.0K | 142,205 | — | ↗ |
| 2020-10-21 | Gurrola Sandra M | Officer | F-InKind | D | Common Stock | 1,178 | 2.05 | 2.4K | 29,540 | — | ↗ |
| 2020-09-22 | Wolff Allen | Director / Officer | F-InKind | D | Common Stock | 170 | 1.99 | 338.30 | 144,658 | — | ↗ |
| 2020-09-22 | Gurrola Sandra M | Officer | F-InKind | D | Common Stock | 97 | 1.99 | 193.03 | 30,718 | — | ↗ |
| 2020-08-25 | Wolff Allen | Director / Officer | F-InKind | D | Common Stock | 170 | 2.62 | 445.40 | 144,828 | — | ↗ |
| 2020-08-25 | Gurrola Sandra M | Officer | F-InKind | D | Common Stock | 98 | 2.62 | 256.76 | 30,815 | — | ↗ |
| 2020-08-13 | ELLIN ROBERT S | 10% Owner | S-Sale | D | Common Stock, $0.005 par value | 170,900 | 5.33 | 910.1K | 16,194 | — | ↗ |
| 2020-07-28 | Wolff Allen | Director / Officer | F-InKind | D | Common Stock | 2,453 | 1.85 | 4.5K | 144,998 | — | ↗ |
| 2020-07-28 | Gurrola Sandra M | Officer | F-InKind | D | Common Stock | 1,178 | 1.85 | 2.2K | 30,913 | — | ↗ |
| 2020-06-29 | Wolff Allen | Director / Officer | F-InKind | D | Common Stock | 170 | 3.15 | 535.50 | 147,451 | — | ↗ |
| 2020-06-29 | Gurrola Sandra M | Officer | F-InKind | D | Common Stock | 97 | 3.15 | 305.55 | 32,091 | — | ↗ |
| 2020-06-17 | ELLIN ROBERT S | 10% Owner | S-Sale | D | Common Stock, $0.005 par value | 12,400 | 6.01 | 74.5K | 187,094 | — | ↗ |
| 2020-06-16 | ELLIN ROBERT S | 10% Owner | S-Sale | D | Common Stock, $0.005 par value | 100 | 3.86 | 386.00 | 199,494 | — | ↗ |
| 2020-06-03 | Berg Jeffrey Alan | 10% Owner | S-Sale | D | Common Stock | 21,932 | 1.10 | 24.1K | 276,100 | — | ↗ |
| 2020-06-02 | Berg Jeffrey Alan | 10% Owner | S-Sale | D | Common Stock | 30,730 | 0.99 | 30.4K | 297,440 | — | ↗ |
| 2020-06-01 | Berg Jeffrey Alan | 10% Owner | S-Sale | D | Common Stock | 30,000 | 1.06 | 31.8K | 328,170 | — | ↗ |
| 2020-05-29 | Berg Jeffrey Alan | 10% Owner | S-Sale | D | Common Stock | 25,000 | 1.06 | 26.5K | 358,170 | — | ↗ |
| 2020-05-28 | Berg Jeffrey Alan | 10% Owner | S-Sale | D | Common Stock | 12,338 | 1.08 | 13.3K | 383,170 | — | ↗ |
| 2020-05-27 | Berg Jeffrey Alan | 10% Owner | S-Sale | D | Common Stock | 5,000 | 1.11 | 5.5K | 395,508 | — | ↗ |
| 2020-05-26 | Berg Jeffrey Alan | 10% Owner | S-Sale | D | Common Stock | 20,000 | 1.09 | 21.8K | 400,508 | — | ↗ |
| 2020-05-20 | Wolff Allen | Director / Officer | F-InKind | D | Common Stock | 164 | 1.55 | 254.20 | 147,621 | — | ↗ |
| 2020-05-20 | Gurrola Sandra M | Officer | F-InKind | D | Common Stock | 115 | 1.55 | 178.25 | 32,188 | — | ↗ |
| 2020-04-21 | Wolff Allen | Director / Officer | F-InKind | D | Common Stock | 2,363 | 1.21 | 2.9K | 147,785 | — | ↗ |
| 2020-04-21 | Gurrola Sandra M | Officer | F-InKind | D | Common Stock | 1,392 | 1.21 | 1.7K | 32,303 | — | ↗ |
| 2020-03-27 | Wolff Allen | Director / Officer | A-Award | A | Common Stock | 9,506 | 1.48 | 14.1K | 150,148 | — | ↗ |
| 2020-03-25 | Wolff Allen | Director / Officer | F-InKind | D | Common Stock | 207 | 1.48 | 306.36 | 139,371 | — | ↗ |
| 2020-03-25 | Gurrola Sandra M | Officer | F-InKind | D | Common Stock | 114 | 1.48 | 168.72 | 33,695 | — | ↗ |
| 2020-03-13 | Wolff Allen | Director / Officer | A-Award | A | Common Stock | 947 | 1.75 | 1.7K | 139,578 | — | ↗ |
| 2020-02-28 | Wolff Allen | Director / Officer | A-Award | A | Common Stock | 778 | 2.13 | 1.7K | 138,631 | — | ↗ |
| 2020-02-25 | Wolff Allen | Director / Officer | F-InKind | D | Common Stock | 285 | 2.05 | 584.25 | 137,853 | — | ↗ |
| 2020-02-25 | Gurrola Sandra M | Officer | F-InKind | D | Common Stock | 115 | 2.05 | 235.75 | 33,809 | — | ↗ |
| 2020-02-14 | Wolff Allen | Director / Officer | A-Award | A | Common Stock | 877 | 1.89 | 1.7K | 138,138 | — | ↗ |
| 2020-01-31 | Wolff Allen | Director / Officer | A-Award | A | Common Stock | 743 | 2.23 | 1.7K | 137,261 | — | ↗ |
| 2020-01-29 | Wolff Allen | Officer | A-Award | A | Common Stock | 5,102 | 0.00 | — | 136,518 | — | ↗ |
| 2020-01-29 | Gurrola Sandra M | Officer | F-InKind | D | Common Stock | 114 | 2.43 | 277.02 | 33,924 | — | ↗ |
| 2020-01-19 | Wolff Allen | Officer | A-Award | A | Common Stock | 75,000 | 0.00 | — | 131,701 | — | ↗ |
| 2020-01-19 | Gurrola Sandra M | Officer | A-Award | A | Common Stock | 25,000 | 0.00 | — | 34,038 | — | ↗ |
| 2019-12-31 | Simtob Richard Isaac | Director | A-Award | A | Common Stock | 3,851 | 0.00 | — | 55,939 | — | ↗ |
| 2019-12-23 | Berg Jeffrey Alan | 10% Owner | S-Sale | D | Common Stock | 200 | 2.45 | 490.00 | 421,100 | — | ↗ |
| 2019-12-20 | ELLIN ROBERT S | 10% Owner | P-Purchase | A | Common Stock, $0.005 par value | 300 | 2.83 | 849.99 | 199,494 | — | ↗ |
| 2019-12-20 | Berg Jeffrey Alan | 10% Owner | S-Sale | D | Common Stock | 1,700 | 2.72 | 4.6K | 421,300 | — | ↗ |
| 2019-12-19 | Wolff Allen | Officer | F-InKind | D | Common Stock | 242 | 2.73 | 660.66 | 56,701 | — | ↗ |
| 2019-12-19 | Gurrola Sandra M | Officer | F-InKind | D | Common Stock | 94 | 2.73 | 256.62 | 9,038 | — | ↗ |
| 2019-12-19 | ELLIN ROBERT S | 10% Owner | P-Purchase | A | Common Stock, $0.005 par value | 299 | 2.72 | 814.30 | 199,294 | — | ↗ |
| 2019-12-05 | ELLIN ROBERT S | 10% Owner | P-Purchase | A | Common Stock, $0.005 par value | 100 | 2.90 | 290.00 | 157,071 | — | ↗ |
| 2019-11-26 | Gottlieb Michael | Director | — | I | Common Stock | 0 | 0.00 | — | 18,986 | — | ↗ |
| 2019-11-20 | Wolff Allen | Officer | F-InKind | D | Common Stock | 241 | 2.62 | 631.42 | 56,943 | — | ↗ |
| 2019-11-20 | Gurrola Sandra M | Officer | F-InKind | D | Common Stock | 95 | 2.62 | 248.90 | 9,132 | — | ↗ |
| 2019-10-29 | ELLIN ROBERT S | 10% Owner | P-Purchase | A | Common Stock, $0.005 par value | 881 | 3.15 | 2.8K | 198,895 | — | ↗ |
| 2019-10-25 | ELLIN ROBERT S | 10% Owner | P-Purchase | A | Common Stock, $0.005 par value | 100 | 3.21 | 321.00 | 198,014 | — | ↗ |
| 2019-10-24 | ELLIN ROBERT S | 10% Owner | P-Purchase | A | Common Stock, $0.005 par value | 202 | 3.03 | 613.03 | 156,971 | — | ↗ |
| 2019-10-23 | Wolff Allen | Officer | F-InKind | D | Common Stock | 241 | 2.88 | 694.08 | 57,184 | — | ↗ |
| 2019-10-23 | Gurrola Sandra M | Officer | F-InKind | D | Common Stock | 94 | 2.88 | 270.72 | 9,277 | — | ↗ |
| 2019-10-23 | ELLIN ROBERT S | 10% Owner | P-Purchase | A | Common Stock, $0.005 par value | 2,295 | 2.70 | 6.2K | 197,914 | — | ↗ |
| 2019-10-14 | ELLIN ROBERT S | 10% Owner | P-Purchase | A | Common Stock, $0.005 par value | 100 | 3.50 | 350.00 | 198,995 | — | ↗ |
| 2019-10-08 | ELLIN ROBERT S | 10% Owner | P-Purchase | A | Common Stock, $0.005 par value | 100 | 3.67 | 367.00 | 195,619 | — | ↗ |
| 2019-10-04 | ELLIN ROBERT S | 10% Owner | P-Purchase | A | Common Stock, $0.005 par value | 28 | 2.93 | 82.04 | 195,519 | — | ↗ |
| 2019-10-03 | ELLIN ROBERT S | 10% Owner | P-Purchase | A | Common Stock, $0.005 par value | 265 | 3.12 | 826.61 | 195,391 | — | ↗ |
| 2019-10-01 | ELLIN ROBERT S | 10% Owner | P-Purchase | A | Common Stock, $0.005 par value | 100 | 3.43 | 343.00 | 195,126 | — | ↗ |
| 2019-09-30 | ELLIN ROBERT S | 10% Owner | P-Purchase | A | Common Stock, $0.005 par value | 100 | 3.33 | 333.00 | 194,926 | — | ↗ |
| 2019-09-26 | ELLIN ROBERT S | 10% Owner | P-Purchase | A | Common Stock, $0.005 par value | 4,831 | 2.95 | 14.2K | 194,826 | — | ↗ |
| 2019-09-25 | ELLIN ROBERT S | 10% Owner | P-Purchase | A | Common Stock, $0.005 par value | 5,150 | 2.81 | 14.5K | 189,995 | — | ↗ |
| 2019-09-24 | Wolff Allen | Officer | F-InKind | D | Common Stock | 722 | 2.28 | 1.6K | 57,425 | — | ↗ |
| 2019-09-24 | Gurrola Sandra M | Officer | F-InKind | D | Common Stock | 454 | 2.28 | 1.0K | 9,321 | — | ↗ |
| 2019-09-24 | ELLIN ROBERT S | 10% Owner | P-Purchase | A | Common Stock, $0.005 par value | 23,550 | 2.44 | 57.5K | 184,845 | — | ↗ |
| 2019-09-13 | ELLIN ROBERT S | 10% Owner | P-Purchase | A | Common Stock, $0.005 par value | 1,551 | 2.27 | 3.5K | 153,963 | — | ↗ |
| 2019-09-12 | ELLIN ROBERT S | 10% Owner | P-Purchase | A | Common Stock, $0.005 par value | 7,451 | 2.26 | 16.9K | 161,295 | — | ↗ |
| 2019-09-11 | ELLIN ROBERT S | 10% Owner | P-Purchase | A | Common Stock, $0.005 par value | 2,200 | 2.31 | 5.1K | 153,844 | — | ↗ |
| 2019-09-10 | ELLIN ROBERT S | 10% Owner | P-Purchase | A | Common Stock, $0.005 par value | 3,700 | 2.56 | 9.5K | 151,644 | — | ↗ |
| 2019-08-30 | Miller Susan Elaine | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-08-27 | Wolff Allen | Officer | F-InKind | D | Common Stock | 141 | 2.77 | 390.57 | 58,147 | — | ↗ |
| 2019-08-27 | Krishnan Ram | Director / Officer | F-InKind | D | Common Stock | 241 | 2.77 | 667.57 | 102,375 | — | ↗ |
| 2019-08-27 | Gurrola Sandra M | Officer | F-InKind | D | Common Stock | 35 | 2.77 | 96.95 | 9,775 | — | ↗ |
| 2019-08-23 | ELLIN ROBERT S | 10% Owner | S-Sale | D | Common Stock, $0.005 par value | 100 | 2.80 | 280.00 | 147,944 | — | ↗ |
| 2019-07-30 | Wolff Allen | Officer | F-InKind | D | Common Stock | 141 | 3.18 | 448.38 | 58,288 | — | ↗ |
| 2019-07-30 | Krishnan Ram | Director / Officer | F-InKind | D | Common Stock | 240 | 3.18 | 763.20 | 102,616 | — | ↗ |
| 2019-07-30 | Gurrola Sandra M | Officer | F-InKind | D | Common Stock | 34 | 3.18 | 108.12 | 9,810 | — | ↗ |
| 2019-07-30 | ELLIN ROBERT S | 10% Owner | P-Purchase | A | Common Stock, $0.005 par value | 8,651 | 3.23 | 27.9K | 148,144 | — | ↗ |
| 2019-07-29 | ELLIN ROBERT S | 10% Owner | — | D | Common Stock, $0.005 par value | 0 | 0.00 | — | 151,512 | — | ↗ |
| 2019-07-01 | Russell Angus C. | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 1.03 | 41.2K | 40,000 | — | ↗ |
| 2019-07-01 | Mulroy Michael H. | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 1.03 | 41.2K | 40,000 | — | ↗ |
| 2019-07-01 | FARRELL STEPHEN C | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 1.03 | 41.2K | 40,000 | — | ↗ |
| 2019-07-01 | BAILEY DON M | Director | A-Award | D | Stock Option (Right to Buy) | 40,000 | 1.03 | 41.2K | 40,000 | — | ↗ |
| 2019-06-30 | Roberts Brandi | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 150,000 | 1.10 | 165.0K | 150,000 | — | ↗ |
| 2019-06-21 | Wolff Allen | Officer | F-InKind | D | Common Stock | 141 | 3.47 | 489.27 | 58,429 | — | ↗ |
| 2019-06-21 | Krishnan Ram | Director / Officer | F-InKind | D | Common Stock | 235 | 3.47 | 815.45 | 102,856 | — | ↗ |
| 2019-06-21 | Gurrola Sandra M | Officer | F-InKind | D | Common Stock | 34 | 3.47 | 117.98 | 9,844 | — | ↗ |
| 2019-06-07 | Yanover Paul | Director | A-Award | A | Stock Options (Right to Buy) | 400 | 3.85 | 1.5K | 400 | — | ↗ |
| 2019-06-07 | Thomas Gregory Matthew | Director | A-Award | A | Stock Options (Right to Buy) | 400 | 3.58 | 1.4K | 400 | — | ↗ |
| 2019-06-07 | Simtob Richard Isaac | Director | A-Award | A | Stock Options (Right to Buy) | 400 | 3.58 | 1.4K | 400 | — | ↗ |
| 2019-06-07 | Mitgang Steve | Director | A-Award | A | Stock Options (Right to Buy) | 400 | 3.58 | 1.4K | 400 | — | ↗ |
| 2019-05-21 | Wolff Allen | Officer | F-InKind | D | Common Stock | 171 | 2.89 | 494.19 | 58,570 | — | ↗ |
| 2019-05-21 | Krishnan Ram | Director / Officer | F-InKind | D | Common Stock | 234 | 2.89 | 676.26 | 103,091 | — | ↗ |
| 2019-05-21 | Gurrola Sandra M | Officer | F-InKind | D | Common Stock | 35 | 2.89 | 101.15 | 9,878 | — | ↗ |
| 2019-04-23 | Wolff Allen | Officer | F-InKind | D | Common Stock | 171 | 3.80 | 649.80 | 58,741 | — | ↗ |
| 2019-04-23 | Krishnan Ram | Director / Officer | F-InKind | D | Common Stock | 277 | 3.80 | 1.1K | 103,325 | — | ↗ |
| 2019-04-23 | Gurrola Sandra M | Officer | F-InKind | D | Common Stock | 34 | 3.80 | 129.20 | 9,913 | — | ↗ |
Executive team
Top executives
Shares Outstanding
314.1K
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Sanjeev Luther, President and Chief Executive Officer | 550.0K | — | — | 324.8K | — | 14.0K | 888.8K | 36.54% | ↗ |
| 2 | 2025 | Sandra Gurrola, Sr. Vice President of Finance | 275.0K | — | — | 43.4K | — | 11.0K | 329.4K | 13.17% | ↗ |
| 3 | 2024 | Sanjeev Luther, President and Chief Executive Officer | 550.0K | 75.0K | — | 2.42M | — | 14.0K | 3.06M | 79.13% | ↗ |
| 4 | 2024 | Sandra Gurrola, Sr. Vice President of Finance | 275.0K | — | — | 110.2K | — | 11.0K | 396.2K | 27.81% | ↗ |
| 5 | 2023 | Matthew Angel, Former Chief Executive Officer and President | 350.0K | — | — | 461.7K | 13.0K | — | 824.7K | 55.98% | ↗ |
| 6 | 2023 | Andrew Jackson, Former Chief Financial Officer ) | 144.6K | — | — | — | — | 217.5K | 362.1K | 0.00% | ↗ |
| 7 | 2023 | Sandra Gurrola, Sr. Vice President of Finance | 255.8K | 50.1K | — | — | — | — | 305.9K | 0.00% | ↗ |
| 8 | 2022 | Howard J. Federoff, Former Chief Executive Officer and President | 182.8K | — | 798.6K | 599.4K | 225.0K | 424.2K | 2.23M | 62.69% | ↗ |
| 9 | 2022 | Matthew Angel, Former Chief Executive Officer and President | — | 211.0K | — | 910.5K | — | 29.8K | 1.15M | 79.08% | ↗ |
| 10 | 2022 | Matthew Angel, Chief Executive Officer and President | — | 211.0K | — | 910.5K | — | 29.8K | 1.15M | 79.08% | ↗ |
| 11 | 2022 | Roger Sidhu, Former Chief Medical Officer | 447.2K | — | 274.4K | 205.9K | — | — | 927.5K | 51.78% | ↗ |
| 12 | 2022 | Kevin D’Amour, Former Chief Scientific Officer | 259.4K | — | 267.1K | 200.5K | — | 175.3K | 902.3K | 51.83% | ↗ |
| 13 | 2022 | Andrew Jackson, Former Chief Financial Officer | 243.7K | — | — | 305.5K | — | — | 549.1K | 55.63% | ↗ |
| 14 | 2022 | Andrew Jackson, Former Chief Financial Officer ) | 243.7K | — | — | 305.5K | — | — | 549.1K | 55.63% | ↗ |
| 15 | 2021 | Howard J. Federoff, Former Chief Executive Officer and President | 318.8K | — | — | 23.61M | 159.4K | — | 24.09M | 98.02% | ↗ |
| 16 | 2021 | Kevin D’Amour, Former Chief Scientific Officer | 212.2K | — | 1.50M | 2.77M | 84.9K | — | 4.57M | 93.50% | ↗ |
| 17 | 2021 | Roger Sidhu, Former Chief Medical Officer | 127.0K | — | 803.3K | 1.49M | 48.3K | — | 2.46M | 92.89% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Sanjeev Luther | Chief Executive Officer, President & Director | 564.0K | male |
| Sandra Gurrola | Senior VP of Finance | 286.0K | female |
| Dorothy J. Clarke | General Counsel | — | female |
| Kanika Chawla | Senior Vice President of Technical Operations (Consultant) | — | — |
| Robert Hamilton Pierce | Chief Scientific Officer | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ERNA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
